

Atara Biotherapeutics (ATRA : US\$52.76)

Atara Biotherapeutics continues uptrend, soars 98% and in top 2% of the market

Atara Biotherapeutics, Inc., soared US\$26.11 (or 98%) year to date in 2015 to close at US\$52.76. This means the stock is among the top 2% of NASDAQ-listed stocks in 2015. Compared with the NASDAQ-100 Index which has risen 3.9% YTD, this is a relative price increase of 94%. The average daily volume of 155,662 shares so far in 2015 was 2.5 times the average daily volume in 2014. In 2015 the market cap has jumped US\$746.6 million.

Fig 1: Stock Summary

Sector	Total Nasdaq Market
Market Cap	US\$1.3 billion
Shares Outstanding	24,360,247
ISIN	US0465131078
PermID	1-5037937603
Relative Strength (3 mo)	96

Fig 2: MCap - A Historical Perspective

	Price	MCap (US\$ M)
Last	US\$52.76	1,285.2

Fig 3: Rank in American Region out of 12,368 stocks

Description	Value	Rank	Quartile
MCap (US\$)	1.3B	2177	Top
Rel Strength 6 Mo (US\$)	96	433	Top

Fig 4: Insider Trades



Fig 5: Turnover Rate & Turnover Period




Fig 6: Trailing 3 months

Turnover	US\$621.7 million
Volume	13,164,004
Volume Index (1 is avg)	1.6

Fig 7: Weekly Price Volume Dynamics (Last 12 Weeks)




Fig 8: Relative Strength




Fig 9: Price/Moving Avg Price [P/MAP200]



Fig 10: Price Change %

Price Change %	Trailing Qtr	Trailing Yr	Tr 3 Yrs
ATRA	43.49		
Total Nasdaq Market	4.1	-2.9	45.28
NASDAQ-100 index	2	14.21	68.08

Fig 11: Shareholder Returns

Trailing quarter: The stock rose 34 times (54% of the time) and fell 29 times (46% of the time). The aggregate volume was 1.6 times average trading of 11.9 million shares. The value of US\$1,000 invested 3 months ago is US\$1,435 [vs 1,020 for the NASDAQ-100 Index] for a capital gain of US\$435.

PVUS\$1,000	Trailing Qtr	Trailing Yr	Trailing 3 Yrs
ATRA	US\$1,435		
Total Nasdaq Market	1,041	971	1,453
NASDAQ-100 Index	1,020	1,157	1,681

Fig 12: Month-on-Month Comparison (Trailing Month - ended 30th)

	30 Jun	29 May	30 Apr	31 Mar	27 Feb	30 Jan
Price 30 Jun (USD)	52.76	42.3	41.51	41.57	19.98	24.51
% Price Change	29.9	-8.5	-3.2	103	-19.1	-10.2
Avg Daily Volume	132,100	112,593	99,171	87,233	75,720	61,510
VWP (USD)	47.22	41.56	36.38	26.48	23.48	26.64
Price Range (USD)	39.21 - 59.5	36 - 49.83	37.1 - 64.35	19.8 - 43.66	17.2 - 25.04	22.54 - 28.27
Relative Price Change %	32.3	-9	-5.1	105.4	-25.8	-7
Volatility %	51.8	38.4	73.4	120.5	45.6	25.4

Fig 13: Recent Analyst Recommendations

Date	Brokerage	Action	Past Rating	Current Rating
16-Jun-2015	Jefferies Group	Boost Price Target	-	Buy
08-May-2015	Jefferies Group	Set Price Target	-	Buy

Fig 14: Reported Selling by Directors

Director	Date	Transaction Type	No. of Shares	Price, USD	Value, USD
Ciechanover Isaac E.	Jun 18, 2015	Sold	2,600	54.41	141,465
Ciechanover Isaac E.	Jun 17, 2015	Sold	2,600	55.03	143,080
Haqq Christopher	Jun 15, 2015	Sold	7,500	46.42	348,116
Mcgrath John	Jun 15, 2015	Sold	10,000	50	500,000
Ciechanover Isaac E.	Jun 04, 2015	Sold	3,800	42.08	159,911
Ciechanover Isaac E.	Jun 05, 2015	Sold	2,600	44.11	114,685

Fig 15: Price Volume Trend: Trailing Quarter



Fig 16: Fibonacci Retracement



Financial Results (Annual)

31 December, 2014

Fig 17: Income Statement

Currency in Thousand of USD	2014-12-31	2013-12-31	Change %
Operating Expenses:			
Research and development	14,380	4,306	Up 234.0
Research and development costs paid to Amgen	1,066	553	Up 92.8
In-process research and development acquired from Amgen			
General and administrative	12,710	3,756	Up 238.4
Total operating expenses	28,156	8,615	Up 226.8
Loss from operations	-28,156	-8,615	Deterioration 226.8
Interest income	125	12	Up 941.7
Loss before provision for income taxes	-28,031	-8,603	Deterioration 225.8
Provision (benefit) for income taxes	25	170	Down 85.3
Net loss	-28,006	-8,773	Deterioration 219.2
Net loss per common share:			
Basic and diluted net loss per common share	-562.0c	-908.0c	Reduced 38.1
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share	4,985,540	965,825	Up 416.2

Fig 18: Balance Sheet

Currency in Thousand of USD	2014-12-31	2013-12-31	Change %
Assets			
Current assets			
Cash and cash equivalents	21,897	51,615	Down 57.6
Short-term available-for-sale investments	82,219		
Prepaid expenses and other current assets	1,910	193	Up 889.6
Total current assets	106,026	51,808	Up 104.7
Property and equipment, net	48	8	Up 500.0
Other assets	48	12	Up 300.0
	96	20	Up 380.0
Total assets	106,122	51,828	Up 104.8
Liabilities, convertible preferred stock and stockholders' equity (deficit)			
Current liabilities:			
Accounts payable	440	606	Down 27.4
Accrued compensation	1,225	331	Up 270.1

Financial Results (Annual) (continued)

31 December, 2014

Income tax payable	1	155	Down 99.4
Other accrued liabilities	1,058	432	Up 144.9
Total current liabilities	2,724	1,524	Up 78.7
Other long-term liabilities	216	230	Down 6.1
	216	230	Down 6.1
Total liabilities	2,940	1,754	Up 67.6
Commitments and contingencies			
Series A convertible preferred stock-0.0001 par value, liquidation preference of 20,088 as of December 31, 2013		109	
Series A-I convertible preferred stock-0.0001 par value, liquidation preference of 3,000 as of December 31, 2013		2,768	
Series B convertible preferred stock-0.0001 par value, liquidation preference of 52,000 as of December 31, 2013		38,414	
Stockholders' equity (deficit):			
Common stock-0.0001 par value, 19,692,937 and 12,003,891 shares 2 issued and outstanding as of December 31, 2014 and 2013, respectively		1	Up 100.0
Additional paid-in capital	144,169	2,200	Up 6,453.1
Notes receivable from stockholder		-335	
Accumulated other comprehensive loss	-100		
Accumulated deficit	-40,889	-12,883	Deterioration 217.4
Total stockholders' equity (deficit)	103,182	-11,017	Recovery
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	106,122	51,828	Up 104.8

Fig 19: Cash Flow

Currency in Thousand of USD	2014-12-31	2013-12-31	Change %
Operating activities			
Net loss	-28,006	-8,773	Deterioration 219.2
Adjustments to reconcile net loss to net cash used in operating activities:			
Non-cash research and development expenses	750		
In-process research and development acquired from Amgen			
Depreciation expense	6	4	Up 50.0
Investment premium amortization, net	526		
Stock-based compensation expense	10,101	1,713	Up 489.7
Interest accrued on notes receivable from stockholder	-2	-4	Improved 50.0
Changes in operating assets and liabilities:			

Financial Results (Annual) (continued)

31 December, 2014

Other assets	-37	27	Deterioration
Prepaid expenses and other current assets	-1,246	-158	Deterioration 688.6
Accounts payable	-164	485	Deterioration
Income tax payable	-154	148	Deterioration
Other accrued liabilities	626	312	Up 100.6
Accrued compensation	894	280	Up 219.3
Other long-term liabilities	78		
Net cash used in operating activities	-16,628	-5,966	Deterioration 178.7
Investing activities			
Purchase of short-term investments	-95,525		
Maturities of short-term investments	12,208		
Purchase of property and equipment	-46	-3	Deterioration 1,433.3
Net cash used in investing activities	-83,363	-3	Deterioration 2,778,666.7
Financing activities			
Proceeds from sale of common stock, net of offering costs	56,455		
Repayment of notes receivable from stockholder	337		
Proceeds from sale of unvested restricted stock			
Proceeds from sale of convertible preferred stock	13,500	53,587	Down 74.8
Offering costs incurred in connection with sale of convertible preferred stock	-19	-210	Improved 91.0
Net cash provided by financing activities	70,273	53,377	Up 31.7
Increase (decrease) in cash and cash equivalents	-29,718	47,408	Deterioration
Cash and cash equivalents-beginning of period	51,615	4,207	Up 1,126.9
Cash and cash equivalents-end of period	21,897	51,615	Down 57.6
Non-cash financing activities			
Issuance of common stock for research and development expenses related to technology licensing option	750		
Issuance of Series A-I convertible preferred stock to Amgen in exchange for license		1,003	
Change in obligation to issue Series A-I convertible preferred stock to Amgen		-1,003	
Issuance of common stock upon vesting of stock awards	90	105	Down 14.3
Change in other long-term liabilities related to non-vested stock awards	-90	226	Deterioration
Restricted stock issued to related party in exchange for notes receivable		331	
Supplemental cash flow disclosure -Cash paid for taxes	70	22	Up 218.2

Financial Results (Annual) (continued)

31 December, 2014

Fig 20: Performance Ratios

	2014-12-31	2013-12-31	Change %
Return on Assets (%)	-26.39	-16.93	Deterioration 55.9
Total Liabilities to Operating Cash Flow	-0.18	-0.29	Improved 39.9
Total Liabilities/Total Assets	0.03	0.03	Down 18.1
Current Ratio	38.92	33.99	Up 14.5

Fig 21: Per Share figures

	2014-12-31	2013-12-31	Change %
Cash	US\$4.39	US\$53.44	Down 91.8
Working Capital	US\$20.72	US\$52.06	Down 60.2
Shareholders' Funds	US\$20.70	-1,140.68c	Recovery
Total Liabilities	58.97c	US\$1.82	Down 67.5
Total Assets	US\$21.29	US\$53.66	Down 60.3
Net Tangible Assets	US\$20.70	-1,140.68c	Recovery
EPS Final	-562.0c	-908.0c	Reduced 38.1

Company Overview

Activities

Atara Biotherapeutics, Inc a clinical-stage biopharmaceutical company focused on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The Company's product candidates are biologics targeting myostatin and activin, members of the Transforming Growth Factor-Beta, or TGF- β , protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues.

Further details can be found at <http://www.atarabio.com>.

Sector Sorting

For Company searches, or for sorting by stocks and variables, an interactive version of today's Table is available [here](#)

8-K people news

June 29: Atara Biotherapeutics Elects 3 Directors

Atara Biotherapeutics (ATRA) held its Annual General Meeting on June 25, 2015. According to an SEC filing under Section 8-K Item 5.07 the following directors were elected:

Eric L. Dobmeier
Beth Seidenberg
Eckard Weber

8-K other news

June 15: Atara Biotherapeutics: Entry into a Material Definitive Agreement

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1604464_000119312515223458_0001193125-15-223458.txt

Source: 8-K United States Securities and Exchange Commission

May 07: Atara Biotherapeutics: Results of Operations and Financial Condition

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1604464_000156459015003599_0001564590-15-003599.txt

Source: 8-K United States Securities and Exchange Commission

February 26: Atara Biotherapeutics: Results of Operations and Financial Condition

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1604464_000156459015001022_0001564590-15-001022.txt

Source: 8-K United States Securities and Exchange Commission

November 12: Atara Biotherapeutics: Results of Operations and Financial Condition

[News Story]
http://www.buysellsignals.net/hbn/8kviewer.jsp?doc=_Archives_edgar_data_1604464_000156459014005468_0001564590-14-005468.txt

Source: 8-K United States Securities and Exchange Commission

Issued Capital

Based on 24,360,247 issued equity shares the market capitalisation is US\$1.3 billion.

The top twenty shareholders hold 44.7% of the issued capital leaving a float of 55.3%.

Fig 22: Top 10 Shareholders

Name of Shareholder	No. of Shares	% Held
Baupost Group Llc/Ma	4,763,265	19.55
Ecor1 Capital Llc	1,063,189	4.36
Visium Asset Management Lp	910,000	3.74
FMR Llc	693,833	2.85
Jennison Associates Llc	594,758	2.44
Bridger Management Llc	474,835	1.95
Neuberger Berman Group Llc	446,777	1.83
Redmile Group Llc	265,205	1.09
Everpoint Asset Management Llc	252,349	1.04
Vanguard Group Inc	216,488	0.89
Total	9,680,699	39.74

Board and Management

Isaac Ciechanover CEO & President & Director

Dr. Isaac Ciechanover is a physician, investor and entrepreneur driven by a passion to improve the practice of medicine. Motivated by the belief that the majority of medical discoveries still lie ahead, he has dedicated the past 20 years to working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He founded Atara Biotherapeutics in August 2012. Previously, he was a partner in the life sciences practice at Kleiner Perkins Caufield & Byers. Earlier as Celgene's Executive Director for Business Development, he spearheaded the company's venture capital efforts and led licensing and M&A activities with an aggregate value of more than \$6.7 billion. Also at Celgene, he was Global Project Leader for the company's first clinical-stage biologic therapy. Isaac has also held business development and venture capital roles at Amylin Pharmaceuticals, Pequet Ventures' healthcare practice and Pfizer. Intellectually curious (and undeterred by student debt), Isaac holds a B.A. from Stanford University, an M.Phil. in Epidemiology from Cambridge University, an M.D. from Weill Cornell Medical College and an M.B.A. from Harvard Business School. For fun, he enjoys cycling, scuba diving and building Lego with his two children. His all-time favorite albums are Pink Floyd's *The Dark Side of the Moon*, Radiohead's *OK Computer* and Ruggero Leoncavallo's Italian opera, *Pagliacci*, with Herbert Von Karajan conducting.

Carol Gallagher Executive Chairman & Director

Carol Gallagher is currently a partner at NEA, a global venture capital firm focused on helping entrepreneurs build transformation businesses across multiple stages, sectors and geographies. Previously Dr. Gallagher was president and CEO of Calistoga Pharmaceuticals where she led a team of executives who advanced the company's lead molecule into full development and secured a successful exit through a \$600 million acquisition by Gilead Sciences. Carol has more than 23 years of experience in commercial and drug development, including roles at Amgen, Aragon Pharmaceuticals, Metastatix, Pfizer, Idec Pharmaceuticals, CancerVax and Anadys Pharmaceuticals. One of her more notable roles was development team leader of Rituxan at Idec Pharmaceuticals, which became Biogen Idec after a merger. Carol attended Vanderbilt University and received her B.S. and Doctor of Pharmacy degrees from the University of Kentucky. In addition to Atara Biotherapeutics, she is an Executive Chair of AnaptysBio and Chairman of eFFECTOR Therapeutics. She also serves as Director for Seragon Pharmaceuticals and Atterocor.

John F. McGrath CFO

John F. McGrath, Jr. joined Atara Biotherapeutics as Chief Financial Officer in January 2013. He was previously Executive in Residence and Operating Partner at Kleiner Perkins Caufield & Byers. John was also Vice President and Chief Financial Officer for Network Equipment Technologies, Inc., which developed and sold network equipment for real-time communications. Earlier in his career, he was Vice President of Finance for Aspect Communications, Director of Finance for TCSI Corporation and Manager in the High Technology and Manufacturing practice at Ernst & Young. John is a registered C.P.A. (inactive) in California and earned a B.S. from the University of Wyoming and an M.B.A. from the Stanford Graduate School of Business. John has served on the board of the Presidio Fund, a publicly traded mutual fund, and as Audit Committee Chairman on the boards of Actel Corporation and Endwave Corporation. Away from work, John enjoys running (including three marathons), swimming and traveling.

Eric Dobmeier Director

Mr. Dobmeier is currently the Chief Operating Officer of Seattle Genetics, Inc., a biotechnology company. Mr. Dobmeier joined Seattle Genetics in March 2002 and has served in positions of increasing responsibility since then, most recently as Chief Business Officer from May 2007 to June 2011. Prior to joining Seattle Genetics, Mr. Dobmeier was an attorney with the law firms of Venture Law Group and Heller Ehrman LLP where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Mr. Dobmeier also serves as a director of Stemline Therapeutics, Inc., a public biotechnology company. Mr. Dobmeier received a J.D. from the University of California, Berkeley School of Law and an A.B. in History from Princeton University. **Creation of shareholder value in Atara Biotherapeutics:** Since appointment as Director: The present value of USD1,000 invested on the appointment date of March 27, 2015 at close price of US\$36.77 is US\$1,237, for a capital gain of US\$237.

Matthew Fust Director

Matthew Fust was Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals from January 2009 through the acquisition of the company in October 2013. From May 2003 to December 2008, Matthew served as Chief Financial Officer of Jazz Pharmaceuticals. From 2002 to 2003, he served as Chief Financial Officer of Perlegen Sciences. Previously, he was Senior Vice President and Chief Financial Officer of ALZA Corporation, where he was an executive from 1996 until 2002. From 1991 until 1996, Matthew was a member of Andersen Consulting's healthcare strategy practice. He received a B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business. Matthew is a director of MacroGenics, Sunesis Pharmaceuticals, and Ultragenyx Pharmaceutical.

Board and Management (continued)

Christopher Haqq Chief Medical Officer

Dr. Christopher Haqq joined Atara Biotherapeutics as Chief Medical Officer in September 2012. He brings 20 years of clinical, academic and drug development experience from biopharma companies large and small. He was recently Vice President for Clinical Research and Development at Cougar Biotechnology and Johnson & Johnson's Janssen, where he was the lead clinician for a pivotal prostate cancer study leading to market approval for Zytiga® (abiraterone acetate). Previously at Amgen, he led early development studies of the anti-insulin like growth factor type 1 receptor AMG 479 (ganitumab) antibody. He has served as medical monitor for more than 10 clinical trials and has contributed to drug development programs for a wide range of molecules. Chris has worked closely with the European Medicines Agency, the U.S. Food and Drug Administration and other global regulatory agencies filing IND applications, new drug applications, special protocol assessments and their international equivalents. Earlier in his career, Chris practiced as a medical oncologist and led a translational science laboratory as an Assistant Adjunct Professor in the Division of Hematology/Oncology at the University of California, San Francisco. In his post-graduate training, also at UCSF, he served as an Intern and Resident in Internal Medicine, Fellow in Medical Oncology and Fellow in Molecular Medicine. Chris completed his M.D. and Ph.D. at Harvard Medical School and his B.S. at Stanford University. He is board certified in Medical Oncology and Internal Medicine. Chris is an inventor of three patents and an author of nearly 50 medical publications. In his free time, he enjoys astronomy and photography.

Glossary

Capital Gain/Loss from n Years Ago to n-1 Years Ago:

Capital Gain or Loss over 1 Year/Price 1 Year Ago (%)

Moving Average Price (n periods) (Fig 9):

Sum of Prices for each Period/Number of Periods

Price Close/Moving Avg Price (Fig 9):

Latest Price/Moving Average Price

Relative Strength (n-th Period) (Fig 1, 8, 3):

Price close today/Price close 'n' periods ago, then ranked by percentile Net Profit/Total Assets (%) within the entire market.

Turnover (Fig 6):

Last Price * Volume

Turnover Rate (Fig 5):

US Dollar value of annual trading volume as a percentage of market capitalisation

Volume Index (Fig 6):

Number of shares traded in the period/Average number of shares traded for the period

Current Ratio (Fig 21):

Current Assets/Current Liabilities (times)

PVUS\$1000 (Fig 11):

Present value of US\$1000 invested 1 year/'n' years ago

Relative Price Change (Fig 12):

Today's Relative price change with respect to Benchmark Index

Return on Assets (Fig 21):

Net Profit/Total Assets (%)

Turnover Period (Fig 5):

Time Period required for trading all Outstanding Shares

Volatility (Fig 12):

Highest Price minus Lowest Price/Lowest Price (%)

Volume Weighted Price (VWP) (Fig 12):

The Volume Weighted Price (VWP) is the summation of turnover divided by total volume in the same period.

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

For further details on definitions and quotations from investing legends, [Click here](#)

For any enquiries, please email: feedback@buysellsignals.com

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate.

The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.